NEW YORK, Sept. 8 Reportlinker.com announces that a new market research report is available in its catalogue.
Autoimmune Disease Therapeutics
Advertisement
http://www.reportlinker.com/p0131243/Autoimmune-Disease-Therapeutics.html
This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Billion by the following therapeutic class - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics only), and Others. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 115 companies including many key and niche players worldwide such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co., Ltd., Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, Novartis AG, Sanofi-aventis SA , Schering-Plough Corporation, Shire Pharmaceuticals Group plc, Teva Pharmaceuticals Industries Limited, and UCB Pharma. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Advertisement
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definition and Scope of Study I-3
Rheumatoid Arthritis I-3
Multiple Sclerosis I-4
Psoriasis I-4
Crohn's disease I-4
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW & OUTLOOK II-1
Autoimmune Disease Therapeutics Market Continues to Flourish II-1
Pharmaceutical Industry Hit by Economic Downturn II-1
Credit Crunch to Affect Biological Drug Pipeline II-1
Biotech Bankruptcies Rife in the Current Economic Downturn II-2
Economic Downturn Takes Toll on R&D II-2
Global Market Estimates and Forecasts II-2
Analysis by Region II-2
Analysis by Segment II-3
2. MARKET DYNAMICS AND TRENDS II-4
Biologics Continue to Gain Market Share II-4
New Products to Drive Market Growth II-4
Biogenerics to Expand Adoption of Biological Drugs II-4
New Indications to Fuel Market Growth II-5
Superior Outcomes to Enhance Adoption of Biologics II-5
Efficacy and Convenience - Key Factors Driving Physician's
Decision II-5
3. DISEASE OVERVIEW II-6
Immunity and Immune System II-6
Autoimmune Diseases II-6
Women- Highly Susceptible to Autoimmune Diseases II-6
Table 1: Percentage Breakdown of Incidence of Autoimmune
Diseases in Men and Women (includes corresponding
Graph/Chart) II-7
Complexity in Manifestations Renders Difficulty in
Understanding the Conditions II-7
Etiology of Autoimmune Diseases II-8
Genetic Predisposition II-8
Environmental Factors II-9
Autoimmune Diseases - A Social and Health Burden II-9
Regulatory Glitches and High Costs Hinder Biogenerics II-9
Types of Autoimmune Diseases II-10
Incidence and Prevalence II-11
Diagnosis and Treatment of Autoimmune Diseases II-11
Overview on Select Biologic Drugs II-11
Remicade II-11
Humira II-12
Rituxan(R) (rituximab) II-12
Cimzia II-13
Cimzia to Face Stiff Competition in Rheumatoid Arthritis Market II-13
Psoriasis - A Promising Market for Cimzia II-14
Actemra II-14
Enbrel II-14
4. OVERVIEW OF SELECT AUTOIMMUNE DISEASES II-15
Rheumatoid Arthritis II-15
Disease Overview II-15
Low Penetration to Sustain growth of Anti-TNF Drugs II-15
Incidence and Prevalence Higher in Urban and Developed Regions II-15
Diagnosis II-16
Treatment of Rheumatoid Arthritis II-16
BRMs Revolutionize RA Treatment II-16
Drugs Used in Treating Rheumatoid Arthritis II-17
Table 2: Leading Biologic Drugs for Rheumatoid Arthritis
Worldwide (2007): Value Sales for Enbrel, Remicade, Humira,
Orencia, Rituxan and Kineret (US$ Million) II-17
Year of Approval of Leading Biologics in Rheumatoid
Arthritis Therapy II-18
Key Drugs In Late Stage Development for Rheumatoid Arthritis
Treatment II-18
Competitive Landscape II-18
Table 3: Comparative Analysis of Leading Biologic Rheumatoid
Arthritis Drugs based on ACR Scores by End Point II-19
High Prices and Safety Concerns II-19
Multiple Sclerosis II-20
Etiology II-20
Types of Multiple Sclerosis II-20
Table 4: Prevalence of Different Types of Multiple Sclerosis II-21
Pathology II-21
Prevalence of Multiple Sclerosis High in Women II-22
Facts About Multiple Sclerosis II-22
Treatment II-22
Interferon Drugs - High Efficacy Drugs in Existing MS Therapies II-23
Beta Interferon Drugs in Multiple Sclerosis Treatment II-23
Non-Interferon Drugs II-23
Non-Interferon Drugs in Multiple Sclerosis Treatment II-24
Trends in Multiple Sclerosis Market II-24
High Unmet Need and Rich Pipeline to Expand MS Market II-24
Interferon-based Drugs Lead Multiple Sclerosis Drug Market II-24
Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies II-25
Dip in Sales Inevitable for Current Therapies II-26
Tough Times Ahead for Betaseron II-26
Competitive Landscape II-27
Table 5: Leading Multiple Sclerosis Drugs Worldwide (2007)
by Sales: Avonex, Rebif, Copaxone, Betaseron and Tysabri
(includes corresponding Graph/Chart) II-28
Table 6: Leading Multiple Sclerosis Drugs Worldwide (2000,
2003 and 2006): Market Shares for Avonex, Rebif, Copaxone,
Betaseron and Tysabri (includes corresponding Graph/Chart) II-28
Multiple Sclerosis Drug Pipeline - An Overview II-29
Drugs Under Development for Treating Multiple Sclerosis II-29
FTY 720 (Fingolimod) II-29
Mylinax II-29
Laquinimod II-30
Campath (Alemtuzumab) - Trials Marred with Side Effects II-30
Teriflunomide II-31
Fampridine-SR II-31
BG-12 (Oral Fumarate) II-31
MN-166 II-31
Psoriasis II-32
Prevalence II-32
Available Treatment Options II-32
Biological Drugs Lead the Fray II-33
Table 7: Leading Psoriasis Drugs Worldwide (2005): Market
Share by Value Sales for Biologics (Enbrel, Raptiva and
Amevive), Systemic Drugs, and Topicals (includes
corresponding Graph/Chart) II-33
Inflammatory Bowel Diseases II-34
Crohn's disease II-34
Stages of the Disease II-34
Prevalence II-34
Diagnosis II-34
Treatment II-35
Global Crohn's Disease Therapeutics Market: Leading
Biological Drugs and their Worldwide II-36
Year of Approval for Leading Drugs in Crohn's Disease
Treatment II-36
Ulcerative Colitis II-36
Diagnosis and Treatment II-36
Other Diseases II-37
Systemic Lupus Erythematosus (SLE) II-37
Prevalence and Epidemiology II-37
Treatment II-37
Sjogren's Syndrome II-38
Prevalence and Epidemiology II-39
Diagnosis and Treatment II-39
Type-1 Diabetes Mellitus II-39
Types of Diabetes Mellitus II-40
Type 1 or Insulin Dependent Diabetes Mellitus II-40
Type 2 or Non-Insulin Dependent Diabetes Mellitus II-40
Insulin - Vital for Blood Glucose Management II-40
Etiology II-40
Prevalence II-41
Diabetes in Children - A Growing Concern II-41
Diagnosis and Treatment II-41
Autoimmune Hepatitis II-42
Disease Categories II-42
Treatment II-42
Side Effects II-42
Juvenile Rheumatoid Arthritis II-43
Symptoms II-43
Diagnosis II-43
Scleroderma II-43
Prevalence II-44
Etiology II-44
Diagnosis II-44
Management II-44
Vasculitis Syndeomes II-44
Haematologic Autoimmune Diseases II-45
Ankylosing Spondylitis II-45
5. PRODUCT INTRODUCTIONS/APPROVALS II-46
Cimzia(R) Receives FDA Approval for Treating Rheumatoid Arthritis II-46
Simponi(TM) Receives FDA Approval for Treating Rheumatoid Arthritis II-46
HUMIRA(R) Obtains EU Approval for Polyarticular Juvenile
Idiopathic Arthritis II-46
Cimzia(R) Receives FDA Nod for Treating Crohn's Disease II-47
HUMIRA(R) Obtains Approval from Japanese Ministry for Rheumatoid
Arthritis II-47
HUMIRA(R) Receives FDA Clearance for Polyarticular Juvenile
Idiopathic Arthritis II-47
Abbott Receives EU Marketing Authorization for Humira in
Psoriasis Treatment II-47
Xian-Janssen Introduces Remicade, Branded infliximab in China II-48
HUMIRA(R) Obtains EU Approval for Treating Crohn's Disease II-48
HUMIRA(R) Obtains FDA Approval for Crohn's Disease II-48
Remicade(R) Obtains Approval for Use in PsA and Early RA in
Australia II-48
Tysabri(TM) Receives Health Canada Approval for Use in Multiple
Sclerosis II-49
Rituxan(R) Gets FDA Approval for Use in RA II-49
Humira(R) Obtains FDA Approval for Treating AS II-49
Betaseron(R) Receives FDA Approval for Use in First Clinical
Episode of MS II-50
Abbott Receives FDA Clearance for HUMIRA Pen II-50
Remicade Obtains FDA Approval for Treating Pediatric Crohn`s
Disease II-50
6. RECENT INDUSTRY ACTIVITY II-52
Novo Nordisk and VLST Collaborate on Therapeutic Targets
Development II-52
Actemra's Approval Gets Delayed II-52
Apitope Raises Financing for Developing Multiple Sclerosis
Compound II-53
CalciMedica to Acquire Rights to STIM1 from TorreyPines II-53
Roche Acquires ARIUS Research, Inc. II-54
Astellas Inks Agreement with Maxygen for MAXY-4 Candidates II-54
Carna and Caliper Life Sciences Ink Collaborative Supply
Agreement II-55
Isotechnika Gets Back Worldwide Rights to Transplant Drug,
Voclosporin II-55
Boehringer In-licenses Two Drug Targets from BioFocus II-56
Bionomics Enters into a Development and Licensing Agreement
with Merck Serono II-56
Nycomed Inks Agreement with Immunomedics for Veltuzumab II-57
EpiVax Receives Grants from National Institutes of Health to
Advance Epi-13 II-57
Boehringer to Takeover Actimis II-58
Antisoma Acquires Xanthus Pharmaceuticals II-58
Merrimack Acquires Funds for Developing Cancer and Autoimmune
Disease Biologics II-59
BioSeek and Merck Sign Collaboration Agreement for Compound
Evaluation II-59
Questcor Amends Distribution Contract with US Distributor of
Acthar II-59
ANP Completes Phase Iia Trial for Multiple Sclerosis Drug II-60
Insert and Calando Merge to Form Calando Pharmaceuticals II-60
Codon Inks Research & Development and Licensing Deal with
Merrimack II-60
Debiopharm Inks licensing Deal with Airmid for Debio 0824 ShK
Peptide II-61
Chelsea Acquires Global Rights to I-3D Range of DHODH
Inhibiting Compounds II-61
Cypress Bioscience Acquires Proprius II-62
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals II-62
GlaxoSmithKline Acquires License to Market Vaccinex's Antibody II-62
Teva to Takeover CoGenesys II-62
Hadasit, HMS and BWH to Co-develop Oral Therapy for Autoimmune
Diseases II-63
Anthera Acquires Rights to Develop and Market AMG 623 from Amgen II-63
Can-Fite Enters into Two Cooperation Agreements to Develop
CF102 Drug II-63
Source MDx Inks an Agreement with Pfizer II-63
Cambridge Inks an Antibody Development Agreement with Medarex II-64
Pfizer to Acquire Coley Pharma II-64
GSK Joins Hands with Tolerx to Develop and Commercialize
otelixizumab II-64
Amgen Acquires Avidia II-65
Eli Lilly and MacroGenics Tie Up for Developing Teplizumab II-66
MorphoSys and Genesis Ink Antibody R&D Deal II-66
arGentis Enters into a License Agreement with UTRF II-67
Eden Biodesign to Investigate Novel Drug Candidate for
Autoimmune Diseases II-67
Nuon and Kissei Team up for Tranilast II-67
Organon and Dyax Team Up for Developing Therapeutic Antibodies II-68
Medarex Joins Hands with Mitsubishi for Monoclonal Antibody
Development II-68
Merck and Archemix Collaborate II-68
Genzyme Takes Over Bioenvision II-69
Organon and Medarex Ink Drug Development Deal II-69
CalciMedica Secures Exclusive Rights for CBR's Autoimmune Drug
Target II-69
Xanthus Secures Exclusive Patent Estate Rights for FLT3 Pathway II-70
Eisai Corporation Acquires Morphotek II-70
TIRC Changes Name to Orchestra Therapeutics II-71
Abbott Files HUMIRA(R) for Psoriasis in the US and EU (USA/Europe) II-71
Accentia Secures Exclusive Global Rights to Revimmune II-71
Medarex and Compugen Ink Collaborative Agreement for
Therapeutic Antibody II-72
SRI and Telik Sign License Agreement for Drug Development II-73
China Biopharma Signs Agreement with Chinese Biopharmaceutical
Firm II-73
Kirin and Astellas Ink Licensing Agreement for Anti-CD40
Antagonistic mAb II-74
QSV and Artielle Sign Contract to Produce RTL-1000 II-74
JDRF and MacroGenics Form Partnership II-75
GSK and Genmad Sign Partnership Agreement for HuMaxCD20 II-75
Biocon Enters into Joint Venture Agreement with Neopharma II-76
Pipex Pharmaceuticals Acquires Remaining Stake in Effective
Pharmaceuticals II-76
Astellas Acquires Worldwide Rights for Amevive(R) II-77
Biogen Acquires Fumapharm II-77
Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy II-77
7. FOCUS ON SELECT GLOBAL PLAYERS II-78
Abbott Laboratories (USA) II-78
Amgen Inc. (USA) II-78
Bayer Schering Pharma AG (Germany) II-79
Biogen Idec Inc. (USA) II-80
Bristol-Myers Squibb Company (USA) II-81
Elan Corporation, plc (Ireland) II-82
Eli Lilly And Company (USA) II-83
F. Hoffmann-La Roche AG (Switzerland) II-83
Chugai Pharmaceutical Co., Ltd. (Japan) II-84
Genentech, Inc. (USA) II-85
GlaxoSmithKline plc (UK) II-86
Johnson & Johnson, Inc. (USA) II-87
Merck Serono SA (Switzerland) II-88
Novartis AG (Switzerland) II-88
Sanofi-aventis SA (France) II-89
Schering-Plough Corporation (USA) II-90
Shire Pharmaceuticals Group plc (Ireland) II-90
Teva Pharmaceuticals Industries Limited (Israel) II-91
UCB Pharma (Belgium) II-92
8. GLOBAL MARKET PERSPECTIVE II-93
Table 8: World Recent Past, Current & Future Analysis for
Autoimmune Disease Therapeutics by Geographic Region - US,
Japan, Europe and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Billion for Years 2006 through 2015
(includes corresponding Graph/Chart) II-93
Table 9: World 10-year Perspective for Autoimmune Disease
Therapeutics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe and Rest of World Markets
for Years 2006, 2009 & 2015 (includes corresponding
Graph/Chart) II-94
Table 10: World Recent Past, Current & Future Analysis for
Rheumatoid Arthritis Therapeutics by Geographic Region - US,
Japan, Europe and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Billion for Years 2006 through 2015
(includes corresponding Graph/Chart) II-95
Table 11: World 10-year Perspective for Rheumatoid Arthritis
Therapeutics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe and Rest of World Markets
for Years 2006, 2009 & 2015 (includes corresponding
Graph/Chart) II-96
Table 12: World Recent Past, Current & Future Analysis for
Multiple Sclerosis Therapeutics by Geographic Region - US,
Japan, Europe and Rest of World- Markets Independently
Analyzed with Annual Sales in US$ Billion for Years 2006
through 2015 (includes corresponding Graph/Chart) II-97
Table 13: World 10-year Perspective for Multiple Sclerosis
Therapeutics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe and Rest of World Markets
for Years 2006, 2009 & 2015 (includes corresponding
Graph/Chart) II-98
Table 14: World Recent Past, Current & Future Analysis for
Psoriasis Therapeutics by Geographic Region - US, Japan,
Europe and Rest of World- Markets Independently Analyzed with
Annual Sales in US$ Billion for Years 2006 through 2015
(includes corresponding Graph/Chart) II-99
Table 15: World 10-year Perspective for Psoriasis Therapeutics
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Japan, Europe and Rest of World Markets for Years
2006, 2009 & 2015 (includes corresponding Graph/Chart) II-100
Table 16: World Recent Past, Current & Future Analysis for
Crohn's Disease Therapeutics (Biologics) by Geographic Region
- US, Japan, Europe and Rest of World- Markets Independently
Analyzed with Annual Sales in US$ Billion for Years 2006
through 2015 (includes corresponding Graph/Chart) II-101
Table 17: World 10-year Perspective for Crohn's Disease
Therapeutics (Biologics) by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Japan, Europe and Rest of
World Markets for Years 2006, 2009 & 2015 (includes
corresponding Graph/Chart) II-102
Table 18: World Recent Past, Current & Future Analysis for
Other Autoimmune Disease Therapeutics by Geographic Region -
US, Japan, Europe and Rest of World- Markets Independently
Analyzed with Annual Sales in US$ Billion for Years 2006
through 2015 (includes corresponding Graph/Chart) II-103
Table 19: World 10-year Perspective for Other Autoimmune
Disease Therapeutics by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Japan, Europe and Rest of
World Markets for Years 2006, 2009 & 2015 (includes
corresponding Graph/Chart) II-104
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Autoimmune Diseases Fact Sheet III-1
Table 20: Prevalence of Key Autoimmune Diseases in the US
for 2006 (in Millions) (includes corresponding Graph/Chart) III-2
Market Trends III-2
Biologic Drugs Lead the Fray III-2
Biologics To Add Further Impetus to the Market III-2
Rheumatoid Arthritis Drugs Lead the Market III-3
Enbrel and Humira Continue to Gain Share in the Anti-TNF
Market III-3
Increased Incidence and Rise in Drug Prices to Drive Growth
in MS Market III-3
Table 21: US Multiple Sclerosis Drug Market (2006):
Percentage Breakdown of Number of Dispensed Prescriptions
for Avonex, Copaxone, Rebif, Betaseron and Tysabri
(includes corresponding Graph/Chart) III-4
Incidence of Type 1 Diabetes Mellitus Endemic in White Youth III-4
Lialda's Share Gaining Momentum in Ulcerative Colitis Drugs
Market III-4
Key Ulcerative Colitis Drugs Market in the US (2006) III-5
Table 22: US Ulcerative Colitis Drugs Market (2007 &
2008): Percentage Breakdown of Prescriptions Dispensed
Ranked by Leading Drugs for Asacol, Pentasa, Lialda,
Canasa, Sulphasalazine, Colazal, Other Drugs and Generics
(includes corresponding Graph/Chart) III-5
Product Launches/ Approvals III-6
Strategic Corporate Developments III-9
Key Players III-28
B.Market Analytics III-36
Table 23: US Recent Past, Current & Future Analysis for
Autoimmune Disease Therapeutics by Disease Segment -
Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's
Disease (Biologics) and Other Autoimmune Diseases
Independently Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-36
Table 24: US 10-year Perspective for Autoimmune Disease
Therapeutics by Disease Segment - Percentage Breakdown of
Dollar Sales for Rheumatoid Arthritis, Multiple Sclerosis,
Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune
Diseases for Years 2006, 2009 & 2015 (includes corresponding
Graph/Chart) III-37
2. JAPAN III-38
A.Market Analysis III-38
Current and Future Analysis III-38
Product Launches/Approvals III-38
Key Players III-38
B.Market Analytics III-39
Table 25: Japanese Recent Past, Current & Future Analysis
for Autoimmune Disease Therapeutics by Disease Segment -
Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's
Disease (Biologics) and Other Autoimmune Diseases
Independently Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding
Graph/Chart) III-39
Table 26: Japanese 10-year Perspective for Autoimmune
Disease Therapeutics by Disease Segment - Percentage
Breakdown of Dollar Sales for Rheumatoid Arthritis, Multiple
Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other
Autoimmune Diseases for Years 2006, 2009 & 2015 (includes
corresponding Graph/Chart) III-40
3. EUROPE III-41
A.Market Analysis III-41
Current and Future Analysis III-41
Europe - A Burgeoning Market for Autoimmune Disease
Therapeutics III-41
Increasing Awareness to Drive Market Growth III-41
Low Penetration to Fuel Growth in European MS DMDs Market III-41
Table 27: Prevalence of Key Autoimmune Diseases in Europe
for 2006 in Millions (includes corresponding Graph/Chart) III-42
Lower Treatment Rate Bodes Huge Potential for the UK MS
Drug Market III-42
Drugs Hindering Disease Progression to Gain Prominence III-42
Product Launches/Approvals III-43
Strategic Corporate Developments III-44
Key Players III-47
B.Market Analytics III-55
Table 28: European Recent Past, Current & Future Analysis
for Autoimmune Disease Therapeutics by Disease Segment -
Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's
Disease (Biologics) and Other Autoimmune Diseases
Independently Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-55
Table 29: European 10-year Perspective for Autoimmune
Disease Therapeutics by Disease Segment - Percentage
Breakdown of Dollar Sales for Rheumatoid Arthritis, Multiple
Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other
Autoimmune Diseases for Years 2006, 2009 & 2015 (includes
corresponding Graph/Chart) III-56
4. REST OF WORLD III-57
A.Market Analysis III-57
Current and Future Analysis III-57
Canada III-57
Canada - Highest Prevalence Rates for Multiple Sclerosis III-57
Sales of Biologics on the Rise in Canadian Rheumatoid
Arthritis Drugs Market III-57
Asia-Pacific III-58
Autoimmune Diseases Market in Asia-Pacific - An Overview III-58
Incidence of Multiple Sclerosis in India on the Rise III-58
Overview of Rheumatoid Arthritis in Australia III-59
Table 30: Percentage Breakdown of Prevalence of
Rheumatoid Arthritis in Australia by Age Group (includes
corresponding Graph/Chart) III-59
Table 31: Percentage Breakdown of Prevalence of
Rheumatoid Arthritis in Australia by Sex (includes
corresponding Graph/Chart) III-60
Overview of Irritable Bowel Diseases in Australia III-60
Product Launches/Approvals III-61
Strategic Corporate Developments III-62
B.Market Analytics III-65
Table 32: Rest of World Recent Past, Current & Future
Analysis for Autoimmune Disease Therapeutics by Disease
Segment - Rheumatoid Arthritis, Multiple Sclerosis,
Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune
Diseases Independently Analyzed with Annual Sales in US$
Billion for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-65
Table 33: Rest of World 10-year Perspective for Autoimmune
Disease Therapeutics by Disease Segment - Percentage
Breakdown of Dollar Sales for Rheumatoid Arthritis, Multiple
Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other
Autoimmune Diseases for Years 2006, 2009 & 2015 (includes
corresponding Graph/Chart) III-66
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 115 (including Divisions/Subsidiaries - 122)
To order this report:
Autoimmune Disease Therapeutics
http://www.reportlinker.com/p0131243/Autoimmune-Disease-Therapeutics.html
More market research reports here!
Contact: Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
